These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

477 related items for PubMed ID: 16024644

  • 1. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins.
    Shimamura T, Lowell AM, Engelman JA, Shapiro GI.
    Cancer Res; 2005 Jul 15; 65(14):6401-8. PubMed ID: 16024644
    [Abstract] [Full Text] [Related]

  • 2. The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor.
    Kobayashi N, Toyooka S, Soh J, Yamamoto H, Dote H, Kawasaki K, Otani H, Kubo T, Jida M, Ueno T, Ando M, Ogino A, Kiura K, Miyoshi S.
    Lung Cancer; 2012 Feb 15; 75(2):161-6. PubMed ID: 21767894
    [Abstract] [Full Text] [Related]

  • 3. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.
    Tracy S, Mukohara T, Hansen M, Meyerson M, Johnson BE, Jänne PA.
    Cancer Res; 2004 Oct 15; 64(20):7241-4. PubMed ID: 15492241
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.
    Sawai A, Chandarlapaty S, Greulich H, Gonen M, Ye Q, Arteaga CL, Sellers W, Rosen N, Solit DB.
    Cancer Res; 2008 Jan 15; 68(2):589-96. PubMed ID: 18199556
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells.
    Xu W, Yuan X, Jung YJ, Yang Y, Basso A, Rosen N, Chung EJ, Trepel J, Neckers L.
    Cancer Res; 2003 Nov 15; 63(22):7777-84. PubMed ID: 14633703
    [Abstract] [Full Text] [Related]

  • 8. Differential effects of Hsp90 inhibition on protein kinases regulating signal transduction pathways required for myoblast differentiation.
    Yun BG, Matts RL.
    Exp Cell Res; 2005 Jul 01; 307(1):212-23. PubMed ID: 15922741
    [Abstract] [Full Text] [Related]

  • 9. Hsp90 inhibition by WK88-1 potently suppresses the growth of gefitinib-resistant H1975 cells harboring the T790M mutation in EGFR.
    Hong YS, Jang WJ, Chun KS, Jeong CH.
    Oncol Rep; 2014 Jun 01; 31(6):2619-24. PubMed ID: 24789511
    [Abstract] [Full Text] [Related]

  • 10. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
    Zou M, Xia S, Zhuang L, Han N, Chu Q, Chao T, Peng P, Chen Y, Gui Q, Yu S.
    Int J Oncol; 2013 Jun 01; 42(6):2094-102. PubMed ID: 23588221
    [Abstract] [Full Text] [Related]

  • 11. Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors.
    Regales L, Balak MN, Gong Y, Politi K, Sawai A, Le C, Koutcher JA, Solit DB, Rosen N, Zakowski MF, Pao W.
    PLoS One; 2007 Aug 29; 2(8):e810. PubMed ID: 17726540
    [Abstract] [Full Text] [Related]

  • 12. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.
    Sordella R, Bell DW, Haber DA, Settleman J.
    Science; 2004 Aug 20; 305(5687):1163-7. PubMed ID: 15284455
    [Abstract] [Full Text] [Related]

  • 13. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM.
    Cancer Res; 2004 Aug 01; 64(15):5355-62. PubMed ID: 15289342
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
    Georgakis GV, Li Y, Rassidakis GZ, Martinez-Valdez H, Medeiros LJ, Younes A.
    Clin Cancer Res; 2006 Jan 15; 12(2):584-90. PubMed ID: 16428504
    [Abstract] [Full Text] [Related]

  • 15. Epidermal growth factor receptors with tyrosine kinase domain mutations exhibit reduced Cbl association, poor ubiquitylation, and down-regulation but are efficiently internalized.
    Padrón D, Sato M, Shay JW, Gazdar AF, Minna JD, Roth MG.
    Cancer Res; 2007 Aug 15; 67(16):7695-702. PubMed ID: 17699773
    [Abstract] [Full Text] [Related]

  • 16. Hsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors.
    Hashida S, Yamamoto H, Shien K, Ohtsuka T, Suzawa K, Maki Y, Furukawa M, Soh J, Asano H, Tsukuda K, Miyoshi S, Kanazawa S, Toyooka S.
    Oncol Rep; 2015 Mar 15; 33(3):1499-504. PubMed ID: 25607753
    [Abstract] [Full Text] [Related]

  • 17. Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer.
    Shimamura T, Perera SA, Foley KP, Sang J, Rodig SJ, Inoue T, Chen L, Li D, Carretero J, Li YC, Sinha P, Carey CD, Borgman CL, Jimenez JP, Meyerson M, Ying W, Barsoum J, Wong KK, Shapiro GI.
    Clin Cancer Res; 2012 Sep 15; 18(18):4973-85. PubMed ID: 22806877
    [Abstract] [Full Text] [Related]

  • 18. The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.
    Normant E, Paez G, West KA, Lim AR, Slocum KL, Tunkey C, McDougall J, Wylie AA, Robison K, Caliri K, Palombella VJ, Fritz CC.
    Oncogene; 2011 Jun 02; 30(22):2581-6. PubMed ID: 21258415
    [Abstract] [Full Text] [Related]

  • 19. The heat shock protein 90-binding geldanamycin inhibits cancer cell proliferation, down-regulates oncoproteins, and inhibits epidermal growth factor-induced invasion in thyroid cancer cell lines.
    Park JW, Yeh MW, Wong MG, Lobo M, Hyun WC, Duh QY, Clark OH.
    J Clin Endocrinol Metab; 2003 Jul 02; 88(7):3346-53. PubMed ID: 12843186
    [Abstract] [Full Text] [Related]

  • 20. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.
    Mukohara T, Engelman JA, Hanna NH, Yeap BY, Kobayashi S, Lindeman N, Halmos B, Pearlberg J, Tsuchihashi Z, Cantley LC, Tenen DG, Johnson BE, Jänne PA.
    J Natl Cancer Inst; 2005 Aug 17; 97(16):1185-94. PubMed ID: 16106023
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.